Inside Precision Medicine November 19, 2024
Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, PhD, CEO of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.”
SSTR2 is one of the receptors for the peptide hormone somatostatin and is highly expressed on neuroendocrine cells and others, where it is involved in neurotransmission, hormone secretion, and cell proliferation.
The global radioligand...
Today's Sponsors
Today's Sponsor